TABLE OF CONTENTS 2 HALF-YEAR MANAGEMENT REPORT 40 A Significant events of the first half of 2022 40 B Progress on implementation of the Corporate Social Responsibility strategy 44 C Events subsequent to

During the first half of 2022, Sanofi continued to implement its new "Play to Win" strategy, involving major decisions and positive actions that will support and rebuild the competitive margins necessary for Sanofi to continue to deliver on its mission. Significant events connected with the implementation of that strategy are described below (for additional information on developments related to Research and Development see also section "A.2. Research and Development" below).

On January 7, 2022, Sanofi announced a research collaboration and license agreement with Exscientia to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscentia's end-to-end AI-driven platform using actual patient samples. The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia's novel bispecific small molecule candidate capable of targeting two distinct targets in inflammation and immunology.

On February 3, 2022, Sanofi unveiled a bold new unifying visual identity that epitomizes the modernization and transformation launched by the company in December 2019. With roots in a variety of diverse companies, Sanofi is today a combination of many cultures, identities, and brands. Its new visual identity is rooted in this heritage and brings this diverse history together in a single common brand for the first time. This latest step on the company's journey symbolizes an ambitious strategy for the future.

On February 8, 2022, Sanofi announced the completion of its acquisition of Amunix Pharmaceuticals, Inc (Amunix), adding a promising pipeline of T-cell engager immunotherapies and cytokine therapies. The acquisition also gives Sanofi access to Amunix's Pro-XTENTM, XPAT, and XPAC technologies to deliver next-generation Conditionally Activated Biologics. This technology platform is highly complementary to Sanofi's existing R D platforms, and is a perfect fit for Sanofi's efforts to accelerate and expand its contribution to developing innovative medicines for oncology patients, with approximately 20 molecules currently in development.

On February 23, 2022, Sanofi and GSK announced their intention to submit data from both their booster and Phase III efficacy trials as the basis for regulatory applications for a COVID-19 vaccine (i) final analysis of data from the global VAT02 booster trial confirmed the vaccine candidate's universal ability to boost neutralizing antibodies 18-to-30-fold regardless of the platform used for primary vaccination (mRNA or adenovirus) (ii) the VAT08 Phase 3 primary series trial demonstrated that two doses of the Sanofi-GSK vaccine in seronegative populations demonstrated efficacy of 100% against severe COVID-19 disease and hospitalizations, 75% against moderate or severe COVID-19 disease, and 57.9% against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in an environment dominated by numerous variants and (iii) the trials demonstrated a favorable safety profile following both primary and booster vaccination.

On March 8, 2022, Sanofi was recognized as one of the most sustainability-committed companies in an Environment, Social, Governance (ESG) evaluation performed by Standard Poor's Global Ratings (S P). The ESG Evaluation awarded Sanofi a score of 86 points out of 100, one of the highest scores across all sectors globally. Sanofi's ESG profile earned 80 points for its solid fundamentals, supplemented by an additional strong preparedness opinion of 6 points awarded for the company's "excellent awareness of risks and opportunities" and capacity to anticipate and adapt to a variety of long-term plausible disruptions".

On March 15, 2022, Sanofi and Blackstone (NYSE BX) announced a strategic risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will invest up to 300 million to accelerate the global pivotal studies and clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa to treat patients with multiple myeloma (MM), due to start on schedule in the second half of 2022.

On March 16, 2022, Sanofi and Seagen Inc. (Nasdaq SGEN) announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein, and Sanofi currently has one ADC in development.

During the March 29, 2022 investor conference, Sanofi gave an update on how the company is advancing its immunology strategy, including its ambition to more than quadruple sales from the Immunology franchise by the end of the decade. The focus of the event was on Dupixent (dupilumab), a key growth driver for Sanofi, and on the company's rapidly advancing pipeline which features dermatological, respiratory and gastrointestinal diseases as priority therapeutic areas. Sanofi has raised its peak sales ambition for Dupixent to more than 13 billion. This new ambition does not include the potential for further upgrades to the sales ambition from chronic obstructive pulmonary disease (COPD), with pivotal readouts from clinical trials in this indication anticipated in 2023.

On March 29, 2022, Sanofi (NASDAQ SNY) and IGM Biosciences, Inc. (Nasdaq IGMS) announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology inflammation targets. Engineered IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies and have ten binding sites, as opposed to conventional IgG antibodies that have only two target binding sites.

On March 30, 2022, Sanofi finalized the terms of a dual-tranche 1.5 billion bond issue. This includes an inaugural issue of sustainability-linked bonds for a nominal amount of 650 million, linked to Sanofi's commitment to improve access to essential medicines in low- and lower-middle-income countries via its non-profit global health unit. This issue demonstrates Sanofi's commitment to society, and to ensure access to healthcare for the world's most vulnerable people.

On April 4, 2022, Sanofi launched its Diversity, Equity Inclusion (DE I) Board, the first of its kind in the pharmaceutical industry to feature outside advisors. Sanofi's DE I Board will include three of the most influential voices in the DE I space, as Board members appointed for a three-year term organizational psychologist and best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE I pioneer and renowned thought-leader Dr. Rohini Anand.

On April 26, 2022, Sanofi announced that it is partnering with McLaren Racing to accelerate manufacturing efficiency and performance in support of its ambition to attain world-class standards of manufacturing excellence. Following a successful pilot in 2021 with McLaren Racing, both companies have decided to extend their collaboration across multiple sites in seven countries, covering more than 100 production lines across all technologies. Learnings from this partnership will provide insights and develop best practices for manufacturing that will then be implemented across Sanofi's global industrial network .

On May 4, 2022, Sanofi launched Foundation S - The Sanofi Collective, its philanthropic endowment fund aiming to promote health for current and future generations. Using donations, partnerships and collective action, Foundation S will focus on three critical areas childhood cancer, the health of communities most vulnerable to the effects of climate change and pollution, and access to lifesaving medicines and vaccines.

On May 30, 2022, the US Food and Drug Administration (FDA) informed Sanofi that its planned Actual Use Trial (AUT) to support the prescription to over-the-counter switch for Cialis (tadalafil) had been placed on clinical hold due to matters surrounding the protocol design. Sanofi's AUT has not yet recruited any patients. Sanofi continues to work with the FDA to move the Cialis program forward and will engage with the FDA in upcoming meetings to determine the next steps.

On June 2, 2022, Sanofi announced the restructuring of its immuno-oncology collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron). Under the amended and restated license and collaboration agreement, Regeneron will obtain worldwide exclusive license rights to Libtayo . The Sanofi and Regeneron global immuno-oncology license and collaboration agreement was originally signed in 2015. Prior to June 2, 2022, the companies had split Libtayo worldwide operating profits equally and co-commercialized Libtayo in the US, with Sanofi solely responsible for commercialization in the rest of the world. In return, Sanofi will receive an upfront payment of $900 million and an 11% royalty on worldwide net sales of Libtayo . Sanofi will also be eligible for a regulatory milestone payment of $100 million, as well as sales-related milestone payments of up to $100 million over the next two years.

On June 8, 2022, Sanofi announced the launch of its first Digital Accelerator to foster its ambition to become a leading digital healthcare company. The Accelerator will develop products and solutions that will support Sanofi's mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).

On May 3, 2022, Sanofi's General Meeting of Shareholders approved the decision to distribute approximately 58% of the share capital of EUROAPI, a European leader in the development, manufacture, marketing and distribution of Active Pharmaceutical Ingredients (APIs), in the form of an exceptional dividend in kind to Sanofi shareholders. On the dividend payment date of May 10, 2022 (further to the admission of EUROAPI shares to listing on the regulated market of Euronext Paris on May 6, 2022), Sanofi divested control over EUROAPI and its subsidiaries, resulting in their deconsolidation from the Sanofi consolidated financial statements as of that date. On June 17, 2022 (the date of delivery of the EUROAPI shares to the French State via the French Tech Souverainet fund), EPIC BPIFrance acquired a 12% equity interest in EUROAPI. Following completion of those transactions, Sanofi retains an equity interest of 30.1% in EUROAPI, which has been accounted for using the equity method since the date of loss of control.

Net sales for the first half of 2022 amounted to 19,790 million, 14.2% higher than in the first half of 2021. At constant exchange rates (CER)1, net sales rose by 8.4%, driven mainly by strong performances for Dupixent . The year-on-year increase also reflects good performances by the Consumer Healthcare franchise, including robust growth for the Cough Cold category and growth for the Vaccines franchise, driven largely by a recovery in sales of Travel and Polio vaccines compared to 2021.

Net income attributable to equity holders of Sanofi amounted to 3,184 million, versus 2,764 million in the first half of 2021. Earnings per share was 2.55, versus 2.21 for the first half of 2021. Business net income2 was 4,594 million, up 22.6% on the first half of 2021, while business earnings per share (business EPS2) was 22.7% higher than in the first half of 2021 at 3.68.

Highlights of Sanofi's Research and Development efforts in the first half of 2022 in the Specialty Care unit included several US and EU regulatory approvals for Dupixent (dupilumab) for the treatment of eosinophilic esophagitis (EoE), and expanding the severe asthma indication to children aged 6 to 11 years, as well as the moderate-to-severe atopic dermatitis (AD) indication to children aged 6 months to 5 years. In addition, an application for approval of prurigo nodularis has been filed in the US.

In chronic spontaneous urticaria (CSU), the Phase III Study B from the CUPID program evaluating Dupixent in patients who were refractory to omalizumab was stopped due to futility based on a pre-specified interim analysis. Although positive numerical trends in reducing itch and hives were observed, the results from the interim analysis did not demonstrate statistical significance for the primary endpoints. The previously reported Phase III trial (Study A), which evaluated a different group of patients who were biologic-na ve, met its primary and all key secondary endpoints at 24 weeks, showing that adding Dupixent to standard-of-care antihistamines significantly reduced itch and hives compared to antihistamines alone. Sanofi remains committed to advancing Dupixent for patients with CSU on antihistamines and is evaluating next steps.

Efanesoctocog alfa, a once-weekly recombinant factor VIII therapy for the treatment of people with hemophilia A, met both primary and secondary endpoints in previously treated patients 12 years of age. The results showed a clinically meaningful prevention of bleeds over a period of 52 weeks, with a median annualized bleeding rate (ABR) of 0 and a mean ABR of 0.71, and a superiority to prior prophylactic

1 Non-GAAP financial measure see definition in D.3., "Net sales".

2 Non-GAAP financial measure see definition in D.2., "Business net income".

factor VIII replacement therapy based on intra-patient comparison. An application for approval was submitted to the FDA. Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA.

In Oncology, the pivotal Phase II AMEERA-3 clinical trial evaluating amcenestrant monotherapy compared to endocrine treatment in patients with locally advanced or metastatic ER+ HER2- breast cancer who progressed on or after hormonal therapies did not meet its primary endpoint of improving progression-free survival (PFS). No new safety signals were observed. In addition, the Phase III clinical trial evaluating the efficacy and safety of amcenestrant compared with tamoxifen in patients with HR+ early breast cancer who have discontinued adjuvant aromatase inhibitor (AI) therapy due to treatment related toxicity (AMEERA-6), enrolled its first participants.

For the treatment of patients with relapsed Multiple Myeloma, latest results from the IKEMA clinical trial evaluating Sarclisa (isatuximab), in combination with carfilzomib and dexamethasone (Kd), demonstrated a median progression free survival (mPFS) of 35.7 months, compared to 19.2 months in patients treated with Kd alone, as evaluated by an Independent Review Committee.

In Neurology, in late June 2022, the FDA placed a partial clinical hold on the Phase III studies of tolebrutinib in multiple sclerosis (MS) and myasthenia gravis (MG). As a result, new enrolment in the US was paused, and participants in the US who had been in the trial for fewer than 60 days had the study drug suspended. Meanwhile, more than two thousand previously enrolled patients around the globe are continuing to receive tolebrutinib. In early July 2022, the FDA provided written notification to Sanofi requesting information pertaining to additional analyses of clinical safety data and some preclinical data. After submission of the response, the FDA can take up to 30 days to render their decision on whether they agree to lift the partial clinical hold, which could occur as early as the fourth quarter of 2022. In the meantime, enrolment in the clinical program continues with revised study protocols, including enhanced safety monitoring, in most countries. Sanofi is working closely with the independent data monitoring committee members and investigators around the world to evaluate the effectiveness of these safety measures.

For an update on our research and development pipeline, refer to Section G of this half-year management report.

The Combined General Shareholders' Meeting of Sanofi was held on May 3, 2022 at Paris Expo Porte de Versailles, under the chairmanship of Serge Weinberg. All resolutions submitted to the vote were adopted by the shareholders. The General Meeting approved the individual company and consolidated financial statements for the year ended December 31, 2021, and also resolved to distribute an ordinary annual dividend of 3.33 per share and an additional dividend in kind in the form of an allocation of EUROAPI shares, at a ratio of one (1) EUROAPI share per twenty-three (23) Sanofi shares held. The payment of the dividend, including both the cash dividend and the dividend in kind, was made on May 10, 2022. The General Meeting also reappointed Paul Hudson, Christophe Babule, Patrick Kron and Gilles Schnepp as Directors, and approved the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent directors. The Board of Directors is comprised of 16 members, of whom six are women and two are Directors representing employees. The Board of Directors retains a large majority of independent Directors.

For a description of the most significant developments in legal and arbitration proceedings since publication of the financial statements for the year ended December 31, 2021, refer to Note B.14. to the condensed half-year consolidated financial statements.

The following events have occurred in respect of litigation, arbitration and other legal proceedings in which Sanofi and its affiliates are involved

Lantus Mylan Patent Litigation (United States)

Mylan (now Viatris) and Biocon announced the launch of their interchangeable pen and vial products in November 2021. The proceedings concerning US Patent Nos. 8,603,044, 8,679,069, 8,992,486, 9,526,844, and 9,604,008 are now closed.

In the New Mexico action concerning the sale and marketing of Plavix , the state court trial is scheduled to commence in January 2023.

Sanofi US received a new Civil Investigative Demand (CID) requesting the production of documents and information relating to Sanofi's trade and pricing practices for its insulin products and or Lantus -related litigation

Illinois State Attorney General's office (CID issued in July 2022, covering the period from 2003 to present).

Insulin Related Litigation

The Harris County, Texas vs. Sanofi-Aventis US LLC, et al. case was dismissed with prejudice in March 2022.

The Miami, Florida vs. Eli Lilly Co. et al. case was dismissed with prejudice in May 2022.

In May 2022, the Attorney General of Arkansas filed a complaint against the three insulin manufacturers, including Sanofi US, and the three largest Pharmacy Benefit Managers (PBMs) (CVS, ESI, and Optum). The complaint is largely identical to the complaint filed by Mississippi. Arkansas purports to sue both on behalf of itself and in its parens patriae capacity. It asserts claims under the Arkansas Deceptive Trade Practices Act, as well as claims for unjust enrichment and civil conspiracy.

On June 7, 2022. Sanofi launched Action 2022, a global employee share ownership plan open to 86,000 employees in 59 countries. The program, like those carried out since 2013, clearly demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve all employees, across all its territories, in the future development and results of the company.

The shares were offered at a subscription price of 80.21, representing a 20% discount to the average of the 20 opening prices of Sanofi shares from May 9 to June 3, 2022. In addition, for every five shares subscribed, employees were entitled to receive one free share (up to a maximum of four free shares per employee). Each employee was able to purchase up to 1,500 Sanofi shares, subject to the maximum legal limit set at 25% of their gross annual salary minus any voluntary payments already made under employee savings schemes (Group Savings Plan and or Group Retirement Savings Plan) during 2022.

Sanofi continues its progress to improve access to medicines

Sanofi's Global Health Unit has announced the establishment of a fund and the launch of Impact

Sanofi Global Health has announced the launch of Impact , a new brand of standard-of-care medicines produced by Sanofi and dedicated to non-profit distribution to at-risk populations in the world's most impoverished countries. The Impact brand, which includes insulin, glibenclamide and oxaliplatin amongst others, will enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries. Considered essential by the World Health Organization, the medicines cover a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer.

Sanofi has also announced the establishment of an Impact fund that will support start-up companies and other innovators that can deliver scalable solutions for sustainable healthcare in underserved regions. By providing inclusive business financing and technical assistance, the fund will complement Sanofi Global Health's mission of leveraging global, regional and local investment to support the training of healthcare professionals and aiding communities in running sustainable care systems.

Sanofi expands access for underserved communities in the US

Uninsured people living with diabetes in the United States will be able to obtain Sanofi insulins (Lantus , Insulin Glargine U-100, Toujeo , Admelog , and Apidra ) from Sanofi's Insulins Valyou Savings Program with a valid prescription for a fixed price of $35 for a 30-day supply. This is an enhancement to the program, which previously offered a 30-day supply of Sanofi insulins for $99, comprising ten boxes of SoloStar pens and or 10 mL vials or 5 boxes of Max SoloStar pens.

The Insulins Valyou Savings Program has helped thousands of people living with diabetes save on their prescription costs since its launch in 2018. In 2021, the program was used over 97,000 times, and provided more than $37 million in savings to people living with diabetes.

This upgrade extends the scope of the program.

Sanofi joins the Beacon of Hope program to address racial inequities in clinical trials, health, and education

Sanofi has announced a collaboration with the Beacon of Hope program to address the root causes of disparities in health and education and to create greater diversity, equity and inclusion across R D in the pharmaceutical industry.

Racial and ethnic minorities have historically been marginalized in clinical research. Sanofi recognizes and supports the urgency to change this situation and help correct this disparity in clinical trial participation.

Launched in July 2021 as a $33.7 million commitment from Novartis and the Novartis US Foundation, Beacon of Hope began as a 10-year collaboration with Morehouse School of Medicine and 26 other Historically Black Colleges and Universities, the Thurgood Marshall College Fund, Coursera, and the National Medical Association, to work together to increase diversity among clinical trial participants and investigators improve access to high-quality education and promising jobs address inherent bias in the data standards used to diagnose and treat disease and find actionable solutions to environmental and climate issues that disproportionately affect health among communities of color.

Access and Pricing Principles at Sanofi

Sanofi has a long history of working with healthcare systems to make its treatments accessible and affordable to patients in need. We understand and share concerns about the affordability of medicines for patients, and encourage countries to improve value in healthcare spending. However, we firmly believe that the pharmaceutical industry is only one of many stakeholders in the healthcare system that can and should contribute to this goal. Given the growing concerns over rising healthcare costs, we have developed an approach to pricing that reflects our commitment to broadly expanding patient access to medicines and vaccines while maintaining sustainable investment in Research Development. Our Access Pricing Principles are founded on two pillars

Clear rationale for pricing and access at the launch of a new medicine or vaccine

Building affordability criteria into pricing considerations for new launches

When we set the price of a new medicine, we hold ourselves to a rigorous and structured process that includes consultation with external stakeholders and considers the following factors

Holistic assessment of the product's value (clinical, social, wellbeing and economic value)

Availability of similar treatments at the time of launch

Ability of market to afford the product

Other factors specific to the product at the time of launch

We disclose more information on our global access and pricing principles on our global website, and on our US pricing policy on the Sanofi US website.

Sustainability-linked bond tied to Sanofi's Access commitments

Sanofi is committed to integrate sustainability within its Play to Win business strategy, as well as within its investment and financing strategy. More than a year after issuing its first sustainability-linked credit revolving facilities, Sanofi successfully placed an inaugural issue of sustainability-indexed bonds linked to access to medicines. The issue, with a nominal amount of 650 million, is tied to Sanofi's commitment to improve access to essential medicines in low- and lower-middle-income countries via its Global Health non-profit unit. This issue demonstrates Sanofi's commitment to society, and to ensure access to healthcare for the world's most vulnerable people.

Building partnerships to support Sanofi's pediatric cancer commitment

In its flagship childhood cancer program, Sanofi aims to work collaboratively across sectors, to advance knowledge in pediatric studies.

In the research field, Sanofi is now one of the partners of the Pediatric Pre-clinical Proof of Concept Platform (ITCC-P4), which aims to enable state-of-the-art upfront preclinical testing of novel molecularly targeted compounds. Sanofi has recently engaged in a Pediatric Oncology Relevant Target collaboration led by the Foundation for the National Institutes of Health (FNIH) to review and prioritize targets.

For the development of innovative clinical trials, Sanofi works closely with experts at MD Anderson Cancer Center, Institut Gustave Roussy, Children's Hospital of Philadelphia, Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. All of these efforts are centered on patient needs, as highlighted by Sanofi's support for childhood cancer advocacy groups including Coalition Against Childhood Cancer (CAC2) and Imagine for Margo.

Sanofi continues its progress to limit its impact on the environment

New CO2 Scope 3 emissions reduction target

As Sanofi's ambitious strategy to minimize its environmental impacts - including on climate change - delivers important progress, we have upgraded our Scope 3 greenhouse gas (GHG) emissions reduction target from the initial 14% to 30% by 2030, as part of our ambition to achieve carbon neutrality by 2030.

In the third quarter of 2021, we pledged to achieve carbon neutrality by 2030 across all our operations and our entire value chain, as well as net zero greenhouse gas emissions by 2050. This brought our target date forward by 20 years compared with our previous pledge, made in 2015 after COP21 and the Paris Agreement. As part of this ambition, GHG reduction targets versus the 2019 baseline were set at 55% by 2030 for operations (Scopes 1 2) and at 14% for the value chain (Scope 3). Those goals have been validated by the Science Based Target initiative (SBTi). Sanofi submitted the Net-Zero Target and the upgraded Scope 3 reduction target to SBTi for validation last May.

Evolutive Vaccine Facility in Singapore low energy intensity and 100% electrified by design

Building a path towards carbon neutrality is not only about revamping or optimizing existing facilities, but also about designing new factories with the lowest possible environmental footprint.

Our new vaccine facility in Singapore maximized its energy efficiency by including energy recovery in all processes. It is 100% electrified, with gas boilers replaced by heat pumps and energy recovery in all processes. All available surfaces are equipped with solar panels to generate renewable electricity. The remaining electricity supply will be sourced from renewable alternatives such as long-term power purchase agreements and renewable energy certificates, with the objective to source 100% renewable electricity by 2030, in line with our RE100 commitment.

ESG dashboard as of the second quarter of 2022

In 2020, when Sanofi renewed its CSR ambitions, we reviewed and updated our portfolio of initiatives. The numbers shown below highlight ongoing progress in the implementation of our integrated CSR strategy.

Data on YTD basis unless stated otherwise

Sanofi Global Health, a non-profit unit formed within the company in April 2021, aims to provide 30 of Sanofi's medicines across a wide range of therapeutic areas to patients in 40 of the lowest income countries. Beyond the products provided, Sanofi Global Health works on integrating programs that ensure optimal care management over time for patients.

Sanofi is also committed to helping 1,000 patients living with rare diseases who have no access to treatments, and will donate 100,000 vials of medicine for their treatments each year. This continues Sanofi's 30-year commitment to patients suffering from rare diseases, such as Fabry, Gaucher or Pompe diseases, for which access to treatment is often limited.

The third initiative on access is to develop a global access plan for all new products, making them available in selected relevant markets within two years of launch.

Sanofi continues its efforts to fight polio and sleeping sickness, two of its legacy programs that address global health issues.

We have been involved in the fight against polio from the beginning, and continue to play a critical role in the delivery of polio vaccines. We have also committed to collaborate with the WHO to eliminate sleeping sickness by 2030.

Part of Sanofi's R D ambition is to develop innovative medicines to eliminate cancer deaths in children.

To contribute to better resource conservation, Sanofi plans to remove all plastic blister packs for its syringe vaccines by 2027. In addition, we are committed to eco-designing all our new products by 2025. To reduce our greenhouse gas emissions by 55% by 2030, all Sanofi sites will use 100% electricity from renewable sources and we have also set a target of carbon neutrality for our car fleet, both by 2030.

1 Baseline recalculated following the spin-off of EUROAPI

In and beyond the workplace

As a global company, we are committed to ensuring that our leaders reflect the communities and patients we serve. We are committed to continue fostering an organization where all employees have equal opportunities to reach positions of responsibility within the company. Our ambition is to have 40% of women in top executive roles and 50% of women in senior leadership roles by 2025. We are continuing our social and economic engagement in the communities where we operate in. Finally, we are embedding our commitment to society in our leaders' career development paths to strengthen the social impact of their decisions.

The ongoing implementation of our social impact strategy has led in recent months to a range of positive updates of the our rank or grade in most of the ESG rankings.